An observational study in Cirrhosis, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by The Cleveland Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 415 studies in Fibrosis with a site in United States — 81 open to participants now, 109 under way, 13 of them phase 3. Fibrosis · United States.
Among the 415 studies in Fibrosis with a site in United States, this one is the 61st largest by planned enrollment of the 84 observational ones that give a count, is one of 11 that started in 2008, is one of 84 observational ones, reaches primary completion later than 75 of the 108 other live ones, and was the 228th registered.
1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.
Browse Fibrosis studies →81 of the 415 studies in Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 50+ · Men only
Medanta, The Medicity, India · Sites in United States, India
Ages 19+
Pulmovant, Inc. · Sites in United States
Ages 18–85
Joseph C. Wu · Sites in United States
Ages 40+
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 6–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 197 Fibrosis studies recruiting now, 112 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
415 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 117 · Phase 3 59 · Phase 4 25
First in 1977; this study’s year is marked. 11 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 157 across 386 observational studies indexed under Fibrosis.
Median enrollment 52 across the 330 interventional studies, 95 across the 84 observational. Of the 273 that completed or were terminated, 125 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
126 of 415 have an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
The Cleveland Clinic has 6 studies filed under Fibrosis — fewer than ten, so there is no comparison to draw.
34 of the studies in Fibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03654053Phase 3VA Office of Research and DevelopmentMulti-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis | 2026-12-31 |
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
| NCT07029243University of California, San FranciscoPrehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis | 2026-12 |
| NCT06812390Anahita Rabiee MD MHSAlbumin Assisted Diuresis in Patients with Cirrhosis and Ascites | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 415 studies in Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cirrhosis is characterized by loss of muscle as well as fat mass, which increases morbidity and mortality before, during, and after liver transplantation. A common mechanism for the reduced muscle and fat mass in cirrhosis is an increased expression of the TGF (transforming growth factor)beta superfamily member, myostatin, in the muscle and adipose tissue. The present study will examine the expression of myostatin, its receptor and intracellular signaling pathways in the skeletal muscle and mesenteric adipose tissue in cirrhotic patients undergoing liver transplantation as compared to healthy controls undergoing planned abdominal surgery. 16 cirrhotic patients will be identified from the transplant list, and 16 healthy controls from outpatient surgery lists. Nutritional assessment will be performed, including anthropometry (triceps skinfold thickness, mid arm circumference), dual energy x-ray absorptiometry (DEXA), and bioelectrical impedance analysis (BIA). Rectus abdominis muscle tissue and omental fat tissue will be harvested in the operating room, and the expression of signaling proteins involved in skeletal muscle protein synthesis will be quantified. The investigator will also quantify the expression of genes involved in lipolysis and lipid synthesis. The investigator anticipates that the expression of myostatin will be higher in the skeletal muscle and adipose tissue of cirrhotics as compared to controls. There will be a reduction in the expression of the signaling proteins that regulate skeletal muscle protein synthesis, as well as the expression of genes regulating lipogenesis. The increased expression of myostatin will also correlate with reduced anthropometric and DEXA measurements of lean body mass and fat mass.
Patients will be identified from the Cleveland Clinic transplant list. All subjects with cirrhosis of any etiology who will undergo liver transplantation will make up the group of cirrhosis patients. The controls will be patients without cirrhosis that are undergoing abdominal surgery will be identified from the operating room list at Cleveland Clinic. Rectus abdominis muscle biopsies will be obtained directly after induction of anesthesia for the procedure.
Inclusion Criteria:
Control
Exclusion Criteria:
Exclusion criteria (controls)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
Procedure: Rectus abdominis muscle biopsy
Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
Procedure: Rectus abdominis muscle biopsy
Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
Determine the difference in myostatin expression between healthy control and cirrhosis patients
The primary outcome of this study is to determine the difference in expression of myostatin in skeletal muscle in a one time biopsy of the Rectus abdominis muscle between healthy controls and cirrhotic patients.
Time frame: 15 minute biopsy
Started Nov 2008 (actual). Primary completion is estimated for Dec 2028, 241 months after the start.
Of 177 non-industry observational studies under Fibrosis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 105. This study's planned 241 months is above that.
Counting every sponsor, half of 186 studies reached it within 49 months; a quarter within 22 and three quarters within 87.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Dec 2028 and completion Dec 2027 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.